StockData
Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc. (COCP) stock

COCPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.01+0.03 (+3.30%)

Close on Nov 17, 2026Market cap $19.46MP/E –Yield –

Cocrystal Pharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Cocrystal Pharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$7.95M. For fiscal 2025 it was -$8.19M. The highest annual figure on record is -$261.42K in fiscal 2010.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$8.19M–
FY2024Dec 31, 2024-$16.49M–
FY2023Dec 31, 2023-$14.67M–
FY2022Dec 31, 2022-$21.44M–
FY2021Dec 31, 2021-$12.72M–
FY2020Dec 31, 2020-$9.83M–
FY2019Dec 31, 2019-$1.56M–
FY2018Dec 31, 2018-$8.29M–
FY2017Dec 31, 2017-$6.90M–
FY2016Dec 31, 2016-$14.66M–
FY2015Dec 31, 2015-$10.32M–
FY2014Dec 31, 2014-$6.01M–
FY2013Dec 31, 2013-$3.69M–
FY2012Dec 31, 2012-$1.59M–
FY2011Dec 31, 2011-$420.95K–
FY2010Dec 31, 2010-$261.42K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.52M–
Q1 FY2026Mar 31, 2026-$2.34M–
Q4 FY2025Dec 31, 2025-$1.74M–
Q3 FY2025Sep 30, 2025-$1.36M–
Q2 FY2025Jun 30, 2025-$2.16M–
Q1 FY2025Mar 31, 2025-$2.94M–
Q4 FY2024Dec 31, 2024-$3.16M–
Q3 FY2024Sep 30, 2024-$5.12M–
Q2 FY2024Jun 30, 2024-$3.70M–
Q1 FY2024Mar 31, 2024-$4.50M–
Q4 FY2023Dec 31, 2023-$3.33M–
Q3 FY2023Sep 30, 2023-$2.68M–
Q2 FY2023Jun 30, 2023-$5.55M–
Q1 FY2023Mar 31, 2023-$3.11M–
Q4 FY2022Dec 31, 2022-$4.89M–
Q3 FY2022Sep 30, 2022-$8.91M–
Q2 FY2022Jun 30, 2022-$3.72M–
Q1 FY2022Mar 31, 2022-$3.91M–
Q4 FY2021Dec 31, 2021-$2.92M–
Q3 FY2021Sep 30, 2021-$5.40M–
Q2 FY2021Jun 30, 2021-$2.62M–
Q1 FY2021Mar 31, 2021-$1.77M–
Q4 FY2020Dec 31, 2020-$2.38M–
Q3 FY2020Sep 30, 2020-$3.06M–
Q2 FY2020Jun 30, 2020-$2.20M–
Q1 FY2020Mar 31, 2020-$2.19M-208.4%
Q4 FY2019Dec 31, 2019-$1.23M–
Q3 FY2019Sep 30, 2019-$1.32M–
Q2 FY2019Jun 30, 2019-$1.03M–
Q1 FY2019Mar 31, 2019$2.02M–
Q4 FY2018Dec 31, 2018-$1.97M–
Q3 FY2018Sep 30, 2018-$2.15M–
Q2 FY2018Jun 30, 2018-$2.09M–
Q1 FY2018Mar 31, 2018-$2.08M–
Q4 FY2017Dec 31, 2017-$1.58M–
Q3 FY2017Sep 30, 2017-$2.19M–
Q2 FY2017Jun 30, 2017-$1.09M–
Q1 FY2017Mar 31, 2017-$2.05M–
Q4 FY2016Dec 31, 2016-$2.30M–
Q3 FY2016Sep 30, 2016-$3.15M–

More Cocrystal Pharma figures

See a number that looks wrong?